The major clinical trial of eplerenone in patients with acute MI and LV dysfunction, EPHESUS, showed a trend towards a greater benefit for women, treated with eplerenone, at 30 days which was not confirmed at 16 months. 117) Furthermore, in an exploratory, post hoc, non-pre-specified analysis of the TOPCAT trial, evidence for sex differences were found.
1
—
—